Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Inciting commensal human papillomavirus immunity to combat cancer.
Journal: Trends in cancer
Published: February 28, 2025
Commensal papillomavirus immunity preserves the homeostasis of highly mutated normal skin.
Journal: Cancer cell
Published: August 29, 2024
Characterization of T-Helper Immune Phenotype in Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE) Endorses a Delayed-Type Hypersensitivity Reaction.
Journal: The American Journal of dermatopathology
Published: December 22, 2023
Perspectives on Use of the Cutaneous Direct Immunofluorescence Assay-Reply.
Journal: JAMA dermatology
Published: May 11, 2022
Assessment of Clinical and Laboratory Use of the Cutaneous Direct Immunofluorescence Assay.
Journal: JAMA dermatology
Published: October 06, 2021
Communication Between Dermatologists and Dermatopathologists via the Pathology Requisition: Opportunities to Improve Patient Care.
Journal: JAMA dermatology
Published: August 04, 2021
Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models.
Journal: Oncotarget
Published: April 16, 2020
A phase 2, multicenter, placebo-controlled study of single-dose squaric acid dibutyl ester to reduce frequency of outbreaks in patients with recurrent herpes labialis.
Journal: Journal of the American Academy of Dermatology
Published: November 05, 2019
Comment on: "Exam of the future or exam of future cheating? Ethical issues surrounding the American Board of Dermatology's new certification examination".
Journal: Journal of the American Academy of Dermatology
Published: January 30, 2019
The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models.
Journal: Oncotarget
Published: May 22, 2018
Last Updated: 09/26/2026